# A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)

> **NCT01265368** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mologen AG** · enrollment: 19 (actual)

## Conditions studied

- Stage IV Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** MGN1601

## Key facts

- **NCT ID:** NCT01265368
- **Lead sponsor:** Mologen AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-08
- **Final completion:** 2018-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265368, "A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01265368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*